IQVIA Holdings: Increased confidence in Technology & Analytical Services (TAS) 

IQVIA’s business fundamentals remain strong, achieving a 5% revenue growth rate and 8.6% growth in adjusted diluted earnings per share in the second quarter of 2024. The company’s revenue and earnings growth were driven by robust performances across their business segments, such as Technology & Analytics Solutions (TAS) and the Clinical segment. In the TAS segment, IQVIA reported growth of about 3% in the first quarter and 4% in the second quarter, excluding COVID-19 and foreign exchange impacts. The company’s diversified TAS offerings, including artificial intelligence (AI) and machine learning (ML) capabilities integrated into clients’ technology infrastructure, are helping to optimize customer engagement and data management. Moreover, this implies 6% to 7% growth for the balance of the year resulting in full-year mid-single-digit growth, consistent with the target established for TAS at the beginning of the year. The growth in TAS revenue is evidence of gradual industry improvements, with customers more focused on mission-critical projects such as new drug launches. The growing traction in TAS solutions underscores IQVIA’s ability to deliver innovative solutions though AI that address the needs of healthcare providers.